A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients with Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Nov 2024 Planned number of patients changed from 18 to 30.
28 Nov 2023 According to a Peptomyc media release, 4 sites in Spain are currently recruiting: the Hospital Universitari Vall d'Hebron in Barcelona, the Instituto Catalan de Oncologia in Barcelona, the Hospital General Universitario Gregorio Maranon in Madrid and the Hospital Universitario Miguel Servet in Zaragoza.
28 Nov 2023 According to a Peptomyc media release, first patient has been treated in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com